AstraZeneca: encouraging data in metastatic breast cancer

(CercleFinance.com) - Over the weekend AstraZeneca and Merck presented data from a Phase III trial showing that Lynparza had encouraging results in metastatic breast cancer.


The study, which was presented at the American Association for Cancer Research (AACR) annual meeting in Chicago, met its primary endpoint of progression-free survival, the drugmakers said.

Results showed that the median overall survival was 19.3 months in patients treated with Lynparza and 17.1 months for patients treated with chemotherapy.

Lynparza is approved in the US for advanced ovarian cancer. Since January 2018, the drug is also approved for the treatment of metastatic breast cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.